Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma.
Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma. Dan Med J. 2015 Aug;62(8):B5144 Authors: Frøsig TM Abstract This review is focused on research within three different areas of tumor immunology: discovery of new T-cell epitopes and a new immunological antigen (reported in Paper I and II), elucidation of the immunological effects of treatment with a hypomethylating drug (reported in Paper III) and discovery of new conditional ligands (reported in Paper IV). Many melanoma-associated T-cell epitopes have been described, but 45% of these are restricted to human leukocyte antigen (HLA)-A2, leaving the remaining 36 different HLA molecules with only a few described T-cell epitopes each. Therefore we wanted to expand the number of T-cell epitopes restricted to HLA-A1, -A3, -A11 and -B7, all HLA molecules frequently expressed in Caucasians in Western Europe and Northern America. In Paper I we focused on the proteins gp100, Mart1, MAGE-A3, NY-ESO-1, tyrosinase and TRP-2, all melanoma-associated antigens frequently recognized by T cells from HLA-A2 patients. On contrary, in Paper II we wanted to investigate the protein Nodal as a novel immunological target. We took advantage of a T-cell epitope mapping platform in which HLA ligands are predicted by computer-based algorithms, further tested in the laboratory by an ELISA...
CONCLUSION: The results demonstrate ethnic, race, age and gender disparities in iCCA incidence and survival, and confirm continued increase in iCCA incidence in the United States. PMID: 29469047 [PubMed - in process]
The infection rate has begun to decline, but there are likely to be many deaths before the flu season finally ends.
Enzalutamide may have a role in prostate cancer therapy, but randomized trials are needed, says Dr Chodak.Medscape Urology
February 23, 2018—(BRONX, NY)—Earlier this week, in a crowded conference room in the Price Center/Block Pavilion, members of the Einstein-Montefiore community hosted a special visit from U.S. Congressman Joseph Crowley (D-NY, 14th District). At his office’s request, Rep. Crowley met with more than a dozen BOLD Buddies, volunteer peer mentors who provide support for cancer patients and survivors in the Bronx. Members of the group shared their personal stories and explained commitment to offer their support, hope and encouragement to others facing cancer and treatment at all stages of disease.
CANCER symptoms usually include an unexplained change in the body ’s normal processes. But, having a pain in your side that doesn’t go away could be a sign of kidney cancer, and you should see a doctor.
Gemtuzumab ozogamicin (Mylotarg) has been recommended for approval in Europe for use in acute myeloid leukemia, but adjuvant sunitinib after kidney cancer surgery was turned down.International Approvals
Norton Healthcare is customizing treatment rooms for the best patient and provider experience.
Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.
Circulating tumor DNA can help differentiate pseudoprogression from true progression in patients with melanoma who are treated with PD-1 inhibitors.